Ocugen, Inc. Announces Signing Of Binding Term Sheet For The License Of Ocu400 Modifier Gene Therapy For Retinitis Pigmentosa In Korea

Ocugen Inc OCGN:

• OCUGEN, INC. ANNOUNCES SIGNING OF BINDING TERM SHEET FOR THE LICENSE OF OCU400 MODIFIER GENE THERAPY FOR RETINITIS PIGMENTOSA IN KOREA

• OCUGEN INC - TO RECEIVE UP TO $11 MILLION IN UPFRONT FEES

• OCUGEN INC - SALES MILESTONES OF $150 MILLION OR MORE IN FIRST 10 YEARS OF COMMERCIALIZATION